国际标准期刊号: 2278-0238

国际药学与生命科学研究与发展杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Revolutionizing Oncological Interventions: Unveiling the Paradigm Shift of Target Cancer Therapies

Dr. Anubhav Chaurasia

This review article explores the transformative impact of targeted cancer therapies, revolutionizing the field of oncological interventions. Emphasizing precision and specificity, targeted therapies selectively attack cancer cells while minimizing harm to healthy tissues. Various modalities, including small molecule inhibitors, monoclonal antibodies, and immune checkpoint inhibitors, are discussed, along with their distinct mechanisms of action. The review highlights clinical successes, challenges of resistance, and the role of predictive biomarkers in personalized medicine. Furthermore, the potential synergies of targeted agents with traditional therapies and emerging prospects in drug delivery systems and gene editing approaches are examined. Targeted cancer therapies represent a paradigm shift in cancer treatment, enhancing patient outcomes and reshaping oncology.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。